Skip to main content

Table 2 Clinical and functional characteristics of the study patients undergoing thoracotomya,b

From: Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions

Anthropometric variables

LC, N = 12

LC-COPD, N = 23

LC-COPD, moderate smokers, N = 8

LC-COPD, heavy smokers, N = 15

Age, years

64 (12)

66 (9)

68 (9)

65 (9)

Male/female, N

8/4

23/0

8/0

15/0

BMI, kg/m2

27 (3)

26 (5)

25 (5)

25 (5)

Smoking history

    

Current smoker: N, %

6, 50

14, 61

3, 37

11, 73

Ex-smoker: N, %

4, 33

9, 39

5, 63

4, 27

Never smoker: N, %

2, 17

0, 0

0, 0

0, 0

Pack-years

41 (14)

60 (18)**

41 (6)

70 (14)§§§

Lung function testing

    

FEV1, % predicted

86 (7)

60 (12)***

61 (12)

60 (14)

FEV,/FVC, % predicted

74 (3)

61 (7)***

60 (7)

62 (8)

DLco, % predicted

96 (15)

74 (20)**

69 (19)

76 (20)

Kco, % predicted

91 (12)

78 (17)*

73 (11)

80 (20)

TNM staging

    

Stage IA: N, %

3, 25

7, 30

3, 38

4, 27

Stage IB: N, %

3, 25

2, 9

1, 13

1, 7

Stage IIA: N, %

0, 0

6, 26

2, 25

4, 27

Stage IIB: N, %

3, 25

2, 9

2, 25

0, 0

Stage IIIA: N, %

3, 25

6, 26

0, 0

6, 39

Stage IIIB: N, %

0, 0

0, 0

0, 0

0, 0

Stage IV: N, %

0, 0

0, 0

0, 0

0, 0

Histological diagnosis

    

Squamous cell carcinoma: N, %

3, 25

9, 39

5, 62

4, 27

Adenocarcinoma: N, %

6, 50

13, 57

3, 38

10, 67

Others: N, %

3, 25

1, 4

0, 0

1, 6

Blood parameters

    

Total leucocytes/µL

8 × 103 (2.3 × 103)

10 × 103 (2.4 × 103)*

9 × 103 (2.4 × 103)

1 × 104 (2.5 × 103)

Total neutrophils/µL

5 × 103 (2.2 × 103)

7 × 103 (2.6 × 103)*

7 × 103 (2.1 × 103)

7 × 103 (2.8 × 103)

Total lymphocytes/µL

2 × 103 (497)

2 × 103 (527)

2 × 103 (386)

2 × 103 (598)

Albumin, g/dL

4.3 (0.2)

6.1 (9.3)

10.4 (16)

4 (0.5)

Total proteins, g/dL

7.2 (0.6)

7.2 (0.4)

7.1 (0.3)

7.2 (0.5)

Fibrinogen, mg/dL

412 (191)

430 (93)

391 (67)

459 (102)

CRP, mg/dL

1.3 (1)

4.9 (7.4)*

3 (4.4)

5.5 (8.4)

GSV, mm/h

22.4 (12.3)

32.2 (25)

23.4 (22.9)

35.3 (25.8)

Ceruloplasmin, g/dL

25.8 (4)

29.9 (8.5)

24.5 (2.1)

31.2 (9)

Body weight loss, kg

    

0: N, %

11, 92

18, 78

6, 74

12, 80

1–4: N, %

1, 8

2, 9

1, 13

1, 7

5–8: N, %

0, 0

3, 13

1, 13

2, 13

  1. FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; DLco, carbon monoxide transfer; Kco, Krogh transfer factor.
  2. aContinuous variables are presented as mean (standard deviation), while categorical variables are presented as the number of patients in each group and percentage of the total population.
  3. bStatistical analyses and significance: *p < 0.05, **p < 0.01, ***p < 0.001, between LC-COPD patients as a group and LC patients; §p < 0.05, §§p < 0.01, §§§p < 0.001, between LC-COPD heavy smokers and LC-COPD moderate smokers in the post hoc analyses. Comparisons of the clinical and physiological variables between LC-COPD as a group and LC patients, as well as between the two groups of LC-COPD patients (moderate and heavy smokers) were assessed using the Student t test. Differences between the study groups in the qualitative variables were assessed using the χ2 test.
Back to article page

Molecular Medicine

ISSN: 1528-3658